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1.1. Graft-versus-host disease (GvHD) after hematopoietic 
stem cell transplantation (HSCT) 
 
Although anticancer effects are related to dose of anticancer agents, 
hematologic toxicities are the most common dose-limiting toxicities. 
HSCT is the transfusion of multipotent hematopoietic stem cell in 
order to recover hematopoiesis after high intensity chemotherapy. 
Thus high intensity conditioning regimen which includes high dose 
chemotherapy followed by HSCT is the only curative therapy of 
majority of hemato-oncologic disease. The number of HSCT 
increased for 10 years from 195 cases in 2004 to 529 cases in 
2014.1 HSCT can be classified by sources of hematopoietic stem 
cells or graft types. Stem cells came collected from the peripheral 
blood, bone marrow, and umbilical cord blood are used in HSCT. In 
autologous transplantation, the patient’s own stem cells are used, 
while the stem cells come from other donor are used in allogeneic 
HSCT.2,3  
After transfusion of allogeneic hematopoietic stem cells, immune 
cells especially T-cells derived from the donor recognize the 
recipients as foreign and attack the host’s cells. The reaction is 
 
called GvHD and GvHD is a severe complication of allogeneic HSCT. 
Transplantation related morbidity and mortality is related to acute 
GvHD, which occurs within 100 days after transplantation.4 Acute 
GvHD commonly attacks the liver, skin, and gastrointestinal tract 
and the severity of acute GvHD is scored according to signs and 
symptoms represented in those organs. Several risk factors of 
GvHD including recipient and donor characteristics, graft properties, 
conditioning chemotherapy and post-HSCT management were 
suggested. The risk for acute GvHD rises with increasing recipient 
age, use of unrelated donor, human leukocyte antigen (HLA) 
mismatch.5  
 
1.2. Strategies for GvHD prophylaxis  
 
Immunosuppression has been the primary pharmacologic strategy to 
prevent GvHD. Methotrexate has been used since the 1950s as a 
way of shutting down T cells through inhibition of dihydrofolate 
reductase and production of thymidylate and purines. The 
calcineurin inhibitors cyclosporine and tacrolimus inhibit T-cell 
proliferation; combinations with methotrexate have successfully 
been used since the 1970s and are the cornerstone of most 
prophylactic regimens.6  
 
Alternate agents were the inosine monophosphate dehydrogenase 
inhibitor mycophenolate mofetil and the mammalian target of 
rapamycin (mTOR) inhibitor sirolimus. Furthermore given the 
central role of T cells in GvHD, T-cell depletion (TCD) has been 
studied since the 1980s as a preventative strategy. Other drugs 
attempt to target cytokine/chemokine-receptor interactions that 
appear integral to development of GvHD. Exciting new success has 
been reported with maraviroc, a CCR5 antagonist that blocks T-cell 
chemotaxis and dramatically decreased the incidence of 
gastrointestinal and liver GvHD.6 
 
1.3. Calcineurin inhibitor-based GvHD prophylaxis regimens 
 
The introduction in the 1980s of two new immunosuppressive 
agents, cyclosporine and tacrolimus, which prevented T-cell 
activation by inhibiting calcineurin, has dramatically improved 
allograft survival rates. Furthermore, in 1986, the first studies 
reporting the superior outcomes of calcineurin inhibitor (CNI)-
based regimens with notable reduction in GvHD and improved 
survival as a result of combination therapy (such as cyclosporine 
plus methotrexate) compared to either agent alone, were 
published. CNI-based therapies have, therefore, been considered 
 
the standard-of-care for GvHD prevention. Cyclosporine was 
originally isolated from fungi and was noted to have 
immunosuppressive effects. This observation led to its use in the 
prevention of allograft solid organ rejection and GvHD after 
allogeneic HSCT. Although cyclosporine and tacrolimus are 
structurally distinct, their mechanisms of action are similar. 
Cyclosporine binds to the cytosolic protein Peptidyl prolyl cis-trans 
isomerase A (also known as cyclophilin), whereas tacrolimus binds 
to the Peptidyl-prolyl cis-trans isomerase FKBP12, and these 
complexes (cyclosporine–cyclophilin or tacrolimus–FKBP12) inhibit 
calcineurin, thereby blocking the dephosphorylation of nuclear 
factor of activated T cells (NFAT) and its nuclear 
translocation. These events prevent NFAT from exerting its 
transcriptional function, resulting in the inhibition of transcription of 
IL-2 and of other cytokines and ultimately leading to a reduced 
function of T-cells.7 
Two multicenter, randomized, prospective trials conducted in the 
mid-1990s demonstrated decreased incidence of acute GvHD with 
the tacrolimus and methotrexate combination compared to 
cyclosporine and methotrexate, but overall survival was not 
significantly different. These findings led some centers to favour 
the tacrolimus and methotrexate combination. Nonetheless, a recent 
 
survey estimated a much higher proportion of centers using 
cyclosporine over tacrolimus-based regimens.7  
 
2. Research Topics 
 
CNIs have played an important role in GvHD prophylaxis and have 
used for a long time. However there are some unmet needs in 
selection of CNIs and dosing in GvHD prophylaxis.  
Although there have been much studies which compared the 
efficacy and safety between tacrolimus and cyclosporine, all of 
studies were conducted in adult HSCT patients. In this situation, the 
majority of the pediatric centers prefered cyclosporine in 
combination with methotrexate for GvHD prophylaxis. Thus a 
comparison study is needed to establish the efficacy and safety of 
tacrolimus in pediatric HSCT patients. The methods and results are 
presented in SECTION I. 
Second, adequate concentrations of CNIs are important to prevent 
GvHD and adverse drug reactions. To maintain concentrations in 
target range, therapeutic drug monitoring is carried out. 
Nevertheless, large inter- and intra-variability in pharmacokinetics 
interrupt maintaining adequate concentrations of CNIs. Thus a 
 
population pharmacokinetic (PopPK) studies of CNIs are needed 
and the methods and results are presented in SECTION II.  
 
3. Overall Results 
 
In SECTION I, a total of 50 pediatric HSCT patients were included. 
The cumulative incidence of grade II to IV acute GvHD was not 
significantly different between tacrolimus and cyclosporine groups 
(75.4% vs. 66.7%, p = 0.910). The cumulative incidence grade III 
to IV acute GvHD was also not significantly different between 
tacrolimus and cyclosporine groups (15.4% vs. 21.6%, p = 0.627) 
Furthermore relapse free survival and non-relapse mortality at 100 
days post-transplantation was not significantly different between 
two groups (100% vs. 91.3%, p = 0.961 and 0% vs. 8.7%, p = 
0.576). All of adverse drug reactions were reported in less than 10% 
of patients. 
In SECTION II, PopPK models of tacrolimus in pediatric HSCT 
patients and cyclosporine in adult HSCT patients were developed. 
PopPK model of tacrolimus included BSA and azole antifungals use 
as covariates. The final model was:  
CL (L/h) = 6.74 × (BSA/1.102)0.552 × 0.4 (if azole antifungals use)  
V (L) = 1160 × (BSA/1.102)0.503 
 
PopPK model of cyclosporine included weight as covariates. The 
final model was:  
CL = THETA (1) × (weight/70)0.419 × EXP(ETA (1)) 
Both models were well validated by bootstrap and VPC. 
  
 
4. Overall Conclusions 
 
In these studies, the efficacy and safety of tacrolimus and 
cyclosporine were compared in pediatric HSCT patients. In 
conclusion the efficacy of tacrolimus was not superior to 
cyclosporine in pediatric patients and both CNIs had a low incidence 
of adverse drug reactions. 
In addition, tacrolimus in pediatric HSCT patients and cyclosporine 
in adult HSCT patients were developed. Using the models, adequate 
dosing of tacrolimus and cyclosporine might be possible.  
Finally these studies might give insight to the optimization 
strategies of CNIs in GvHD prophylaxis. 
 
Keywords: Calcineurin inhibitors, Tacrolimus, Cyclosporine, 
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SECTION I:  
Comparison of Effectiveness and 
Safety of Calcineurin Inhibitors in 
Pediatric HSCT Patients  
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1.  Introduction 
 
GvHD is a severe complication of allogeneic HSCT. Several 
immunosuppressive strategies were developed to prevent acute 
GvHD. Among these, calcineurin inhibitor (CNI)-based regimens 
are the most commonly used.8 CNIs, cyclosporine and tacrolimus, 
prevent T-cell activation by inhibiting calcineurin. After 
introduction of CNI-based regimen, GvHD incidence was notably 
reduced and survival after HSCT was improved. The combination of 
CNIs with methotrexate has shown superior efficacy over single 
agent use and the combination therapy has become the most widely 
used GVHD prophylaxis regimen.8 Other combination regimen which 
includes mycophenolate mofetil and CNIs also has shown a 
synergistic effect for GvHD prophylaxis.9 There have been some 
researches which compared the efficacy of cyclosporine and 
tacrolimus. Of the two CNIs, tacrolimus-based regimens were 
associated with a statistically significant reduction in acute GvHD 
(RR 0.62, 95% CI 0.52 to 0.75) and in severe acute GvHD (RR 0.67, 
95% CI 0.47 to 0.95) compared to cyclosporine-based regimens. 
However, tacrolimus-based regimens were associated with a 




Children are at less risk for acute GvHD than adults. However, 
acute GvHD risk is still high when using unrelated donor sources.11 
Acute GvHD prophylaxis regimen is not well established in pediatric 
HSCT patients yet. The European Group for Blood and Marrow 
Transplantation (EBMT) Working Party Paediatric Diseases 
(EBMT-WP PD) and the International BFM Study Group -
 Subcommittee Bone Marrow Transplantation (IBFM-SG) evaluated 
current local standards in the prevention of acute GvHD. Several 
conferences with their members assessed practices which are 
mainly applied or under investigation in pediatric patients. As a 
result, the majority of the pediatric centers prefered cyclosporine in 
combination with methotrexate for GvHD prophylaxis.12 Because the 
result conflicted to that of the meta-analysis, a prospective study is 
needed to compare the efficacy and safety of tacrolimus with 
cyclosporine in pediatric HSCT patients.  
The aim of this study was to compare the efficacy and safety of 








A multicentre prospective study was conducted to compare the 
efficacy and safety of tacrolimus with cyclosporine. This study was 
approved by the institutional review board and followed the 
recommendations of the Declaration of Helsinki.  
Pediatric patients who need GvHD prophylaxis after allogeneic 
HSCT were included. Eligibility criteria were age less than 18 years 
old, total bilirubin less than 1.5 times of upper limit of normal 
(ULN), alanine aminotransferase and aspartate aminotransferase 
less than 2.5 times of ULN, serum creatinine less than 1.5 times of 
ULN, and alkaline phosphatase less than 2.5 times ULN. Patients 
with human immunodeficiency virus, severe or uncontrolled 
comorbidity, and previous history of HSCT or solid organ 
transplantation were excluded.  
 
GvHD prevention regimen 
 
Patients received either tacrolimus or cyclosporine in combination 
with methotrexate. Tacrolimus was administered intravenously at 
0.03 mg/kg/day from day -1 and changed to oral from around day 
20 at a 4 times of the last intravenous dosage. Cyclosporine was 
administered intravenously at 3 mg/kg/day from day -1 and 
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changed to oral from around day 20 at a 2 to 3 times of the last 
intravenous dosage. Mehtotrexate was given intravenously at 15 
mg/m2 on day 1 and at 10 mg/m2 on days 3, 6 and 11 after 
HSCT.  Tacrolimus dosing was adjusted to maintain concentrations 
at 10 to 20 ng/mL, while cyclosporine dosing was adjusted to 
maintain whole blood trough concentrations at 200 to 300 ng/mL. 
Drugs for prophylaxis of infection or veno-occlusive disease were 




Patient’s demographic information including sex, age, weight, height, 
original disease, cells source, conditioning regimens were collected. 
All patients were followed up until 100 days post-transplantation. 
During the period, signs and symptoms of acute GvHD, adverse 
drug reactions, and infections were monitored. 
The primary efficacy outcome was the incidence of grade II to IV 
acute GvHD which was a clinically important acute GvHD. The 
grade of acute GvHD was scored according to the stage of liver, 
skin, and gastrointestinal tract involvement.13  
6 
 
The secondary efficacy outcomes were the incidence of grade III to 
IV acute GvHD (severe acute GvHD), relapse free survival at day 
100 post-transplantation, and non-relapse mortality at day 100 
post-transplantation.  
The safety outcomes were adverse drug reactions and infections. 
Adverse drug reactions were evaluated about the relevance with 
tacrolimus or cyclosporine according to Naranjo algorithm.14 Only 
“definitely”, “probably” or “possibly” related adverse drug reactions 




To calculate the sample size, it was assumed that approximately 20% 
of patients in tacrolimus group would experience grade II to IV 
acute GvHD while 55% of patients in cyclosporine group would 
experience grade II to IV acute GvHD. A sample size of 24 
evaluable subjects per study group allowed detection of an absolute 
difference of 35% (one-sided alpha = 0.05, power = 0.80). Thus 
the expected sample size was 26 subjects per study group, 
adjusting 10% drop-out rate. 
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Statistical analysis was conducted by SPSS version 21. A Kaplan-
meier survival analysis and a log-rank test were used to assess 
significance of differences in cumulative incidence of grade II to IV 
acute GvHD, grade III to IV acute GvHD, relapse free survival, 






Twenty six patients in tacrolimus group and twenty four patients in 
cyclosporine group were included. Two patients in tacrolimus group 
were dropped-out because of engraftment failure and non-
compliance. Patient and transplantation characteristics of the study 
population are summarized in Table 1. There were no differences in 
recipient age, sex, cells source, HLA matching, and conditioning 
regimen. Especially more than 90% of patients in both group 







Sixteen patients in cyclosporine group and nineteen patients in 
tacrolimus group. The cumulative incidence of grade II to IV acute 
GvHD was not significantly different between tacrolimus and 
cyclosporine groups (75.4% vs. 66.7%, p = 0.910). The cumulative 
incidence grade III to IV acute GvHD was also not significantly 
different between tacrolimus and cyclosporine groups (15.4% vs. 
21.6%, p = 0.627) (Figure 1). In Cox proportional hazard model, 
type of CNIs (p = 0.235), recipient age (p = 0.398), conditioning 
regimen (p = 0.051), original disease (p = 0.078), sex (p = 0.157), 
degree of HLA matching (p = 0.48), and number of methotrexate 
administration (p = 0.069) were not affected the incidence of grade 
II to IV acute GvHD. However degree of HLA matching significantly 
affected the incidence of grade III to IV acute GvHD (p = 0.013).  
 
Relapse free survival and non-relapse mortality 
 
Relapse free survival at 100 days post-transplantation was not 
significantly different between tacrolimus and cyclosporine groups 
(100% vs. 91.3%, p = 0.961). (Figure 2) Two patients in 
cyclosporine group relapsed after HSCT. Both patients were acute 
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lymphoblastic leukemic patients and one patient relapsed on day 51 
while the other relapsed on day 85.  
Non-relapse mortality was also not significantly different between 
tacrolimus and cyclosporine groups (0% vs. 8.7%, p = 0.576). 
(Figure 2) Two patients in cyclosporine group died.  
 
Adverse drug reactions and infections  
 
Nephrotoxicity (7.7%), hypertension (3.8%), and thrombotic 
microangiopathy (3.8%) were reported in tacrolimus group. 
Otherwise skin rash (8.3%), hypertension (4.2%), urticarial (4.2%), 
and diarrhea (4.2%) were reported in cyclosporine group. All of 
adverse drug reactions were reported in less than 10% of patients. 
(Table 2) 
Cytomegalovirus was the most frequently reported pathogens in 
both tacrolimus and cyclosporine groups (26.9% vs. 41.7%). Other 
pathogens were Enterococcus (3.8%), mycoplasma (3.8%), BK 
virus (3.8%), respiratory syncytial virus (3.8%), and Epstein-Barr 
virus (7.7%) in tacrolimus group. Otherwise Enterococcus (12.5%), 
Klebsiella pneumoniae (4.2%), Escherichia coli (4.2%), BK virus 
10 
 
(4.2%), Ebstein-Barr virus (4.2%), and fungi (8.3%) in 




This study was the first pediatric exclusive study. Although 
children have less risk of acute GvHD, none of study was conducted 
in pediatric population in our knowledge.  
The efficacy of tacrolimus was not superior to cyclosporine in 
pediatric patients. Previous meta-analysis which compared 
tacrolimus/methotrexate regimen and cyclosporine/methotrexate 
regimen included three trials. There was a significant reduction of 
grade II to IV acute GvHD with tacrolimus/methotrexate (RR = 0.62, 
95% CI = 0.52-075). Similarly, there was a significant reduction in 
grade III to IV acute GvHD with tacrolimus/methotrexate (RR = 
0.67, 95% CI = 0.47-0.95). However there was no difference in 
all-cause mortality between tacrolimus/methotrexate and 
cyclosporine/methotrexate groups (RR = 1.10, 95% CI = 0.93-1.3). 
The included studies were published during 1998~2001. After the 
publication of the meta-analysis, several articles were published 
which conflicted with the result of the meta-analysis.  
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Most recently, a retrospective nationwide survey was published and 
a comparison was conducted stratified by stem cell source. 
Incidence of acute GvHD after matched related donor was 
significantly lower in tacrolimus group (21.6% vs. 31.6%, p = 
0.006). In subgroup analysis, stem cells derived from peripheral 
blood induced a lower GvHD incidence in tacrolimus group (21.9% 
vs. 33.8%, p = 0.04) while stem cells from bone marrow did not 
(21.4% vs. 29.4%, p = 0.08). Incidence of acute GvHD was not 
significantly different between tacrolimus and cyclosporine groups 
after unrelated bone marrow stem cell transplantation (38.3% vs. 
42.6%, p = 0.06).15 Because the study was conducted in Japan, 
there was no stem cells derived from unrelated peripheral blood. 
Another international retrospective study suggested insignificant 
results. All of transplantation from sibling bone marrow, sibling 
peripheral blood, unrelated bone marrow, and unrelated peripheral 
blood did not shown significant differences of acute GvHD in 
tacrolimus and cyclosporine groups (p = 0.12, 0.83, 0.98, and 0.47, 
respectively).16 Grade III to IV acute GvHD, overall survival, and 
non-relapse mortality were not significantly different in those two 
studies. The insignificant results in grade II to IV acute GvHD, 
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grade III to IV acute GvHD, relapse free survival, and non-relapse 
mortality were in accordance with those studies.  
In our study the incidence of adverse drug reactions was low. 
Previously tacrolimus in pediatric HSCT patients caused 
hypomagnesemia (58%), nephrotoxicity (12%), tremor (12%), 
hyperglycemia (4%), and hypertension (8%) in a retrospective 
study.17 In another study, hypomagnesemia (98%), hypertension 
(49%), nephrotoxicity (34%), tremor (32%), hyperglycemia (7%), 
and tremor (5%) were reported.18 Application of Naranjo algorithm 
might be the reason of the lower incidence of adverse drug 
reactions in this prospective study. Concurrent use of medications 
such as conditioning regimens, infection prophylactic regimens 
could induce several adverse drug reactions. Also the complications 
of an infusion with hematopoietic stem cells of cryopreserved 
marrow or peripheral blood include cardiac alterations, dyspnea, 
nausea, vomiting, allergic reactions, hypotension, hypertension, 
tremors, fever, chest pain, and feeling of constriction in the larynx, 
abdominal cramps, and exhalation of a characteristic odor for 24 to 
36 hours.19  
There were several limitations in this study. First sample size of 
the study did not fulfilled the number planned. Second, protocols 
13 
 
except for immunosuppressive regimen were different among study 
centers. 
The strength of this study was that study population was specific. A 
low birth rate increased cases of unrelated donor transplantation. 
Furthermore stem cells derived from donor’s peripheral blood 
reduced the inconvenience of donor compared to bone marrow. 
Thus study in unrelated peripheral blood stem cell transplantation 
might be more valuable. 
In this study, we compared the efficacy and safety of tacrolimus and 
cyclosporine in pediatric HSCT patients. In conclusion the efficacy 
of tacrolimus was not superior to cyclosporine in pediatric patients 




Table I-1. Patient demographics  
Characteristics Tacrolimus 
(N = 26) 
Cyclosporine 
(N = 24) 
p-value 
Age, median (range) 10 (1-17) 9 (1-18) 0.365 
Male, n(%) 17 (65.4) 13 (54.2) 1.0 
Cell source, n(%)   1.0 
 Peripheral blood 
stem cells 
24 (92.3) 23 (95.8)  
 Bone marrow 2 (7.7) 1 (4.2)  
HLA matching, 
n(%)f 
  1.0 
 Full matched 19 (73) 17 (71)  
Conditioning 
regimens, n(%) 
  1.0 





Table I-2. The adverse drug reactions (ADRs) and infections 




ADRs 0 2 (8.3%) 
Skin rash 2 (7.7%) 0 
Nephrotoxicity 1 (3.8%) 1 (4.2%) 
Urticaria 0 1 (4.2%) 
Diarrhea  0 1 (4.2%) 
Thrombotic 
microangiography 
1 (3.8%) 0 
Infections   
 Cytomegalovirus 7 (26.9%) 10 (41.7%) 
 Enterococcus 1 (3.8%) 3 (12.5%) 
 Klebsiella  0 1 (4.2%) 
 Mycoplasma  0 1 (4.2%) 
 BK virus 1 (3.8%) 0 
 Respiratory syncytial virus 1 (3.8%) 1 (4.2%) 
 Epstein-Barr virus 2 (7.7%) 1 (4.2%) 





















SECTION II: Model-based approach 




SECTION II-1: PopPK Study of Tacrolimus in 




Tacrolimus, a calcineurin inhibitor, is used for prevent a graft-
versus-host disease (GvHD) in hematopoietic stem cell 
transplantation (HSCT). To prevent GvHD, maintaining adequate 
concentrations of tacrolimus is necessary in HSCT patients. 
Furthermore oversuppression can lead to serious nephrotoxicity, 
neurotoxicity, infections, and increased risk of further malignancies. 
However a narrow therapeutic range and large inter- and intra-
individual pharmacokinetic variability are challenging in spite of 
routine therapeutic drug monitoring (TDM).  
Factors suggested to affect the pharmacokinetics of tacrolimus 
include the population studied, hepatic function, post-
transplantation days, patient age, race, hematocrit and albumin 
concentrations, food administration, corticosteroid dosage, diarrhea, 




Population pharmacokinetic analysis are adding to the understanding 
of the pharmacokinetics of tacrolimus. The population 
pharmacokinetic (PopPK) models could explain those covariate 
effects to pharmacokinetic parameters and suggest personalized 
doses. Previously many studies developed tacrolimus PopPK 
models in various transplantation types. Most were conducted in 
solid organ transplantation patients. However, the gastro-intestinal 
integrity of HSCT patients is physiologically different from that of 
solid organ transplantation patients because of barrier destroy 
secondary to conditioning chemotherapy, GvHD, and infections.21 
Furthermore, concurrent medications like itraconazole, a known 
CYP3A4 inhibitor, are usually administered to prevent infection, and 
can alter tacrolimus pharmacokinetics.  
Furthermore pediatrics have different pharmacokinetic properties 
compared to adults. First absorption can be different because of the 
differences in gastric pH and stomach emptying time that have been 
observed in the pediatric population. A lower plasma protein 
concentrations and a higher body water composition can change 
drug distribution. Metabolic processes are often immature at birth, 
which can lead to a reduced clearance and a prolonged half-life for 
those drugs for which metabolism is a significant mechanism for 
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elimination. The expression of CYP3A4, 2C9, and 2C19 occurs 
during the first weeks of life. Renal excretion is also reduced in 
neonates due to immature glomerular filtration, tubular secretion, 
and reabsorption.22  
Nevertheless, there are few PopPK studies of tacrolimus in HSCT 
patients. In 2001, first PopPK study was reported which included 
122 HSCT patients aged 13~60 years.23 And another PopPK study 
was conducted in 68 Chinese HSCT patients.24 However there is 
only one study that exclusively conducted in pediatric HSCT 
patients. The study identified that the clearance (CL) of tacrolimus 
was influenced by serum creatinine and bioavailability (F) of 
tacrolimus was affected by post-transplantation days. According to 
the model, the authors concluded that current intravenous dose 
recommendations of 0.03 mg/kg/day may produce potentially toxic 
drug concentrations in this patient population, whereas current oral 
conversion of 4 times the adjusted intravenous dose may lead to 
subtherapeutic concentrations. Although the study suggested new 
initial dosage recommendations and a conversion factor of 6, there 
was a limitation that the results were deducted from 22 patients.25  
Thus the aim of this study was to develop a PopPK model of 
tacrolimus in a large population of pediatric HSCT patients and 
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Patients and data 
 
Eligibility criteria were pediatric patients at age less than 18 years 
old, who were going to receive allo-HSCT at a tertiary care 
academic hospital (Seoul, Korea) between September 2006 and 
February 2015 and receive tacrolimus as immunosuppressant 
therapy. Our study was approved by the institutional review board 
and followed the recommendations of the Declaration of Helsinki.  
Patients received tacrolimus and methotrexate for GVHD 
prophylaxis. Tacrolimus was administered by 24-hour continuous 
infusion at an initial dose of 0.03 mg/kg/day and converted to oral 
administration as soon as possible. The initial daily dose of oral CsA 
was equal to four times the last infusion dose and CsA was given in 
two divided doses 12 hours apart. The dose was adjusted according 
to trough therapeutic drug monitoring (10–20 ng/mL). 
The following data were collected retrospectively from electronic 
medical records: age, sex, weight, height, body surface area, post-
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transplantation days, white blood cells, hemoglobin, hematocrit, 
platelets, total bilirubin, alkaline phosphatase, alanine transaminase, 
aspartase transaminase, serum creatinine, glomerular filtration rate, 
albumin, cholesterol, gastrointestinal GvHD, concomitant steroid 
dose, co-administered CYP interacting drugs (azole antifungals, 
proton-pump inhibitors, calcium channel blockers, and phenytoin). 
Dependent variable was tacrolimus trough concentrations which 
were analysed by liquid chromatography-tandem mass 
spectrometry for therapeutic drug monitoring. 
 
Population pharmacokinetic modeling  
 
A PopPK model was developed using the nonlinear mixed-effects 
modeling software program NONMEM (version. 7.3; ICON 
Development Solutions, Hanover, MD, USA). Parameters were 
estimated by the first-order conditional estimation using the 
interaction (FOCE-I) method. The concentration-time data after 
both intravenous and oral routes of administration were fitted 
simultaneously.  
Various compartmental distribution models and absorption models 
were compared during base model building step. The bioavailability 
(F1) was estimated using logit-transform model to keep F1 
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between 0 and 1 for oral administration data. Inter-individual 
pharmacokinetic parameter variability was tested using the additive, 
proportional, and exponential models. Inter-occasional variability 
was incorporated to each week during first month and each month 
after that. A combined model was used for residual error. 
Potential covariates were tested by forward selection and backward 
elimination to determine if these potential covariates affected the 
CsA pharmacokinetic parameters. The influence of covariates on 
the pharmacokinetic parameters was tested by linear, exponential, 
and power function models. Continuous covariates were centralized 
by median values and some were also analyzed as categorical 
covariates with normal or abnormal values. A significant level of P < 
0.05 (ΔOBFV (objective function value) > 3.84) was used in 
forward selection and P < 0.01 (ΔOBFV (objective function value) 
> 6.63) was used in backward elimination process. The modeling 
process was controlled by statistical criteria and visual inspection.  
The final model were validated using bootstrap and prediction 
corrected visual predictive check (pcVPC). One thousand samples 
for bootstrap and pcVPC were simulated by the software program 
PsN (Perl speaks NONMEM version. 4.2.0) and R software version. 
3.1.0. The parameters estimated from the bootstrap were compared 
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Population pharmacokinetic modeling 
 
The characteristics of the 100 patients are presented in Table 1. A 
total of 2,632 therapeutic drug monitoring data were collected. 
Intravenous and oral tacrolimus data were successfully modeled 
simultaneously. A one-compartment model with fixed absorption 
rate constant was the best fit to the data. The estimated parameters 
were population mean value of clearance (CL), volume of 
distribution (V), log-transformed bioavailability (FLGT) and 
absorption rate constant for transit compartment (ka). For inter-
individual variability (IIV) and inter-occasional variability (IOV) the 
exponential model for CL and V yielded the smallest OBFV and the 
best visual fitting.  
During stepwise covariate model building process, body surface 
area (BSA) and azole antifungals use were incorporated into CL and 
BSA was incorporated into V.  
CL (L/h) = 6.74 × (BSA/1.102)0.552 × 0.4 (if azole antifungals use)  
V (L) = 1160 × (BSA/1.102)0.503 
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Because weight, height, and age showed co-linearity with BSA, 
those covariates were excluded in the process. Although the effects 
of other demographic, clinical and variables on the pharmacokinetic 
parameters (CL, V, FLGT) of tacrolimus were evaluated during a 
stepwise process, significant associations were not found.  
The final estimate of typical CL, V and ka was 6.74 L/h, 1,160 L, and 
4.48 h-1, respectively. The typical value of logit-transformed 
bioavailability of oral tacrolimus was estimated as -0.529 thus the 
value of F1 was 0.371. The final estimated pharmacokinetic 




The diagnostic plots of the final model which show the relationship 
between the observed concentrations (DV) and population model-
predicted concentration (PRED) or individual model-predicted 
concentration (IPRED) indicated a good fit between the model and 
the data (Figure 1). The plots of conditional weighted residuals 
(CWRES) vs. PRED and the CWRES vs. time were symmetrically 
distributed and were mostly within 3 units of the null ordinate, 
indicating a good fit of the model to the data (Figure 1). 
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Most of the 1,000 bootstraps ran successfully. The 2.5th percentile 
and 97.5th percentile results are described in Table 2. The 
estimates of each value calculated by NONMEM were near the 
center of the bootstrap runs. The pcVPC showed the median and 
95th percentile of the simulated data captures the median and 95th 
percentile of the observed PK data while the simulated 5th 




This study was the first large PopPK study of tacrolimus in 
pediatric HSCT patients. The base model of tacrolimus was one-
compartment model with fixed ka, because concentration data were 
collected retrospectively and most of them were trough 
concentration. The IIV and IOV were incorporated into CL and V 
with exponential model. The IOV incorporation into the model 
reduced statistically significant spurious period effects and it is the 
strength of this study. 
In the final model, BSA affected both CL and V of tacrolimus. Over 
the years, many studies revealed that BSA was related with CL and 
V of drugs.26 In pediatric oncology, the typical range of BSA is 0.4–
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2 m2. In such a population, for almost any drug, there is a 
correlation between CL and BSA. It is obvious that for children a 
scale parameter such as BSA or weight for dose calculation is 
absolutely necessary.27  
Azoles antifungal agents also significantly affected CL of tacrolimus. 
The use of azoles reduced CL by 60%. Tacrolimus is a well-known 
drug that is metabolized by CYP3A4 and azoles antifungal agents 
inhibit the enzyme activity. Especially most patients received 
itraconazole which is a potent inhibitor of CYP3A4.28 
The estimated value of bioavailability was as high as 37.1%, which 
was higher than common value of 25%. In normal gut, enteral 
metabolism of tacrolimus by gastrointestinal CYP3A isoenzymes 
and excretion to gut lumen by P-glycoprotein transporter is 
extensive. Especially P-glycoprotein lowers intracellular 
concentration of tacrolimus by pumping absorbed drug back out into 
the gut lumen. However conditioning chemotherapy, gastrointestinal 
infections because of low immune activity, and gastrointestinal 
GvHD damage to CYP3A isoenzyme and P-glycoprotein transporter. 
The lower gastrointestinal intensity in HSCT patients explains 
higher bioavailability.  
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Several limitations existed in this study. First because of the nature 
of retrospective study, most of concentration data were the trough 
concentration. Thus the estimation of absorption phase was 
constrained and literature value of absorption rate constant was 
used. Second information about factors affecting the 
pharmacokinetics of tacrolimus such as diarrhea, genetic 
polymorphisms were not evaluated. Pharmacokinetics of tacrolimus 
may be influenced by diarrhea because of changes in 
gastrointestinal transit time. And genetic differences in CYP3A and 
P-glycoprotein expression also affect pharmacokinetic properties 
of tacrolimus.20  
This study showed that BSA significantly influenced the CL and V 
of tacrolimus in the model. Thus BSA-based dosage regimen of 
intravenous and oral tacrolimus would be appropriate in pediatric 
HSCT patients. Furthermore dosage adjustments are necessary 
when azoles antifungal agents initiate or discontinue. High 
bioavailability suggests that the conventional oral conversion ratio 





Table II-1. Patient demographics (N = 100) 
Characteristics N = 100 
Male, n (%) 53 (53.0) 
Age, median (range), year 10 (0.58–17.99)  
Body weight, median (range), kg 33.7 (7.65-72.4) 
Height, median (range), cm 142.2 (66.1-181.9) 
Disease type, n (%) 
Leukemia 65 (65.0) 
Aplastic anemia 20 (20.0) 











Median (2.5th, 97.5th) 
CL (L/h) 6.74 (10) 5.42, 8.06 6.74 (5.52-8.05) 
V (L) 1160 (6) 1024, 1296 1163 (1035-1301) 
FLGT -0.53 (42) -0.96, -
0.09 
-0.53 (-0.94, -0.1) 
ka (h
-1) 4.48 fix   
Impact of 
azoles on CL  
0.4 (16) 0.27, 0.53 0.39 (0.29, 0.54) 
Impact of BSA 
on CL  
0.55 (13) 0.41, 0.69 0.55 (0.39, 0.69) 
Impact of BSA 
on V  
0.50 (15) 0.35, 0.65 0.50 (0.35, 0.64) 
IIV of CL 
(CV%) 
30.2 (9) 24.9, 35.5 29.5 (24.5, 35.0) 
IIV of V (CV%) 31.9 (18) 20.6, 43.2 31.3 (20.3, 43.4) 
IOV of CL, V 
(CV%) 
30.1 (7) 26.0, 34.2 30.0 (26.5, 34.4) 
Residual error 






0.60 (16) 0.41, 0.79 0.58 (0.36, 0.76) 
CI, confidence interval; CL, clearance; CV, coefficient of variation; 
FLGT, log-transformed bioavailability; IIV, inter-individual 
variability; IOV, inter-occasional variability; ka, absorption rate 
constant; RSE, relative standard error; V, volume of distribution 
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SECTION II-2: PopPK Study of Cyclosporine in 




Cyclosporine (CsA) is a commonly used immunosuppressant for 
prevention of graft-versus-host disease (GVHD) in allogeneic 
hematopoietic stem cell transplants (allo-HSCT).29 CsA has a 
narrow therapeutic range and large inter- and intra-individual 
pharmacokinetic variability.30 Many studies have examined the role 
of genetic polymorphisms in CsA pharmacokinetic variations. 
CYP3A5 *3 polymorphism, a single nucleotide polymorphism (SNP) 
in the gene encoding the enzyme CYP3A5, is the most studied and 
influential polymorphism.31 Because vitamin D receptors (VDR) 
control the expressions of several CYP genes, VDR genetic 
polymorphisms could also affect CsA pharmacokinetics.32 Other 
important genetic polymorphisms are variations in ABCB1, which 
encodes the drug transporter P-glycoprotein (P-gp). P-gp has a 
role in preventing oral absorption and promoting clearance into 
bile.33 In ABCB1, the most influential SNPs are 3435C>T, 
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2677G>T/A, and 1236C>T.34 Furthermore, several studies have 
also evaluated the effects of other genetic polymorphisms in 
CYP2C19, CYP2C8, ABCC2, and TGFB1 on CsA 
pharmacokinetics.35,36 
Because of individual variability, it is challenging to maintain CsA 
levels adequate enough to suppress the immune system while 
avoiding side effects. Population pharmacokinetic (PopPK) modeling 
appears to be the best method to predict individual CsA 
pharmacokinetic parameters.37 At present, PopPK models for CsA 
identified in our PubMed and Embase searches have been 
established mostly in solid organ transplants. However, the 
intestinal integrity of allo-HSCT patients is physiologically 
different from that of solid organ transplant patients because of 
mucositis secondary to conditioning regimen, GVHD, and 
infections.21 Furthermore, concurrent medications like fluconazole, a 
known CYP3A4 and CYP2C19 inhibitor, are usually administered to 
prevent infection, and can alter CsA pharmacokinetics. 
Nevertheless, PopPK studies of CsA in allo-HSCT are scarce and 
only one PopPK study has evaluated genetic polymorphisms as 
covariates in allo-HSCT. 
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Therefore, the goal of our study was to build a PopPK model of CsA 
in allo-HSCT in consideration of CYP3A5, CYP2C19, VDR, ABCB1, 





Patients and data 
 
Eligibility criteria were patients at age 18 years or older, who were 
going to receive allo-HSCT at a tertiary care academic hospital 
(Seoul, Korea) between November 2009 and March 2011 and 
receive CsA (Neoral; Novartis Pharma, Basel, Switzerland) as 
immunosuppressant therapy. Exclusion criteria included current 
significant disease that could affect the study: severe psychiatric 
comorbidity; addiction to drugs or alcohol; and pregnancy or 
breast-feeding. All participants gave written informed consent. Our 
study was approved by the institutional review board and followed 
the recommendations of the Declaration of Helsinki.  
Patients received CsA and methotrexate for GVHD prophylaxis. 
CsA was administered by 24-hour continuous infusion and 
converted to oral administration as soon as possible. The initial 
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daily dose of oral CsA was equal to two to three times the last 
infusion dose and CsA was given in two divided doses 12 hours 
apart at least one hour after meals. The dose was adjusted 
according to trough therapeutic drug monitoring (150–400 ng/mL). 
The following data were collected from electronic medical records: 
age, sex, weight, height, red blood cells, hemoglobin, hematocrit, 
platelets, total bilirubin, alkaline phosphatase, alanine transaminase, 
aspartase transaminase, serum creatinine, glomerular filtration rate, 
albumin, cholesterol, concomitant steroid dose, co-administered 
CYP interacting drugs. 
 
CsA blood concentration assay 
 
Whole blood samples (1 mL) were transferred into Vacutainer 
tubes with sodium heparin (Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA) at one time point during continuous 
infusion, prior to dosing and 1, 2, 3, 4, and 5 h after dosing when 
the oral dose reached steady state. Steady state was assumed to be 
reached in 4–5 half-lives after regular dosing is started (median 
half-life 4.43 h).38 All samples were stored at -70°C until 
analysis. CsA concentrations in whole blood were analyzed by liquid 
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chromatography coupled with tandem mass spectrometry (LC-
MS/MS). LC was performed using a Waters 2795 Alliance HT LC 
system (Waters, Milford, CT, USA) with a C18 column (5 μm, 2.1 
mmφ × 150 mm). The Waters Quatro Premier XE system (Waters, 
Milford, CT, USA) was used to measure analytes as positive ions 
by MS/MS. The lower limit of quantification was 100 ng/mL. 
Between 100–5000 ng/mL, the accuracy was 98.5%–103.3% and 




Whole blood samples were collected for genotyping before stem cell 
transplantation. The genotype of the CYP3A5 *1/*3 polymorphism 
was screened using a TaqMan fluorogenic 5′ nuclease assay (Life 
Technologies, Grand Island, NY, USA). The 5 µL polymerase chain 
reaction (PCR) contained 10 ng of genomic DNA and 2.5 µL of 
TaqMan Universal PCR Master Mix with 0.13 µL of 40X Assay Mix 
(Assay ID C_26201809_30). The thermal cycling conditions were 
as follows: initial incubation at 50°C for 2 min and denaturation at 
95°C for 10 min, followed by 45 cycles of annealing at 95°C for 
15 s and extension at 60°C for 1 min. All PCRs were performed in 
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a Dual 384-Well GeneAmp PCR System 9700 (Life Technologies), 
and the endpoint fluorescent readings were performed on an ABI 
PRISM 7900 HT Sequence Detection System (Life Technologies).   
Polymorphism genotyping for the CYP2C19 *1/*2/*3 variant, 
ABCB1 3435C>T, 1236C>T, and 2677G>T/A, ABCC2 -24C>T and 
1249G>A, and VDR Bsml and Apal was analyzed by a SNaPshot 
assay (ABI PRISM SNaPshot Multiplex Kit, Life Technologies). The 
SNaPshot assay was performed according to the manufacturer’s 
instructions. Analysis was carried out using GeneMapper software 
(version 4.0; Life Technologies). Duplicate samples and negative 
controls were included to ensure accuracy in genotyping. 
  
Population pharmacokinetic modeling  
 
A PopPK model was developed using the nonlinear mixed-effects 
modeling software program NONMEM (version. 7.2; ICON 
Development Solutions, Hanover, MD, USA). Parameters were 
estimated by the first-order conditional estimation using the 
interaction (FOCE-I) method. Because the concentration-time data 
after both intravenous and oral routes of administration were fitted 
simultaneously, subroutine ADVAN13 of the NONMEM program 
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was selected to describe the pharmacokinetics of CsA expressed by 
differential equation.  
One- vs. two-compartmental distribution models and lagged time 
vs. transit compartment absorption models were compared during 
base model building step. The bioavailability (F1) was fixed to 1 for 
intravenous data or estimated using logit-transform model to keep 
F1 between 0 and 1 for oral administration data. Inter-individual 
pharmacokinetic parameter variability was tested using the additive, 
proportional, and exponential models. A combined model was used 
for residual error. 
Age, sex, weight, height, red blood cells, hemoglobin, hematocrit, 
platelets, total bilirubin, alkaline phosphatase, alanine transaminase, 
aspartate transaminase, serum creatinine, glomerular filtration rate, 
albumin, cholesterol, concomitant steroid dose, co-administered 
CYP interacting drugs, and genetic polymorphisms were tested by 
forward and backward selection to determine if these potential 
covariates affected the CsA pharmacokinetic parameters. The 
influence of covariates on the pharmacokinetic parameters was 
tested by linear, exponential, and power function models. 
Continuous covariates were centralized and some were also 
analyzed as categorical covariates with normal or abnormal values. 
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Genetic covariates including CYP3A5 *1/*3, CYP2C19 *1/*2/*3, 
ABCB1 3435C>T, 1236C>T, 2677G>T/A, ABCC2 -24C>T, 
1249G>A, and VDR Bsml and Apal polymorphisms, and diplotype 
combinations of the three ABCB1 variants were analyzed as 
categorical covariates. When the number of patients with 
homozygous mutant was less than five, the dominant model (wild 
type vs. heterozygous + homozygous mutant) was used to evaluate 
mutation effect. Further combination of CYP3A5, CYP2C19 
genotype, and use of CYP interacting drugs was also analyzed. A 
significant level of P < 0.05 (ΔOBFV (objective function value) > 
3.84) was used in forward and backward selection process. The 
modeling process was controlled by statistical criteria and visual 
inspection.  
The stability and performance of the developed final model were 
evaluated using bootstrap and prediction corrected visual predictive 
check (pcVPC). One thousand samples for bootstrap and pcVPC 
were simulated by the software program PsN (Perl speaks 
NONMEM version. 4.2.0) and R software version. 3.1.0. The 
parameters estimated from the bootstrap were compared with the 








The characteristics of the 34 patients are presented in Table 1. A 
total of 104 blood samples were collected at a median of 2.5 days 
(range: 1.5-3.5 days) after intravenous CsA was started and when 
converted to oral formulation. All samples were collected at more 
than 4-5 half-lives of CsA. The median (range) dose of 
intravenous CsA was 230 mg/day (145-400 mg/day) and that of 
oral CsA was 300 mg/day (150-700 mg/day), respectively. Nine 
individuals (26.5%) were taking steroids at the time of sampling. 
Prednisolone, methylprednisolone, and dexamethasone were used, 
and the prednisolone converted dose ranged from 5 to 62.5 mg. 
Fluconazole, a CYP isoenzyme inhibitor, was administered orally to 
19 patients for infection prophylaxis at the sampling time for 
intravenous CsA. Voriconazole was administered orally to two 
patients to treat invasive aspergillosis at the sampling time for oral 
CsA. Among them, one patient used both fluconazole and 
voriconazole, but the drugs were not administered at the same time. 
Phenobarbital, which induces CYP isoenzymes, was co-
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administered to two patients. All genotype frequencies of CYP3A5, 
CYP2C19, ABCB1, ABCC2, and VDR were in Hardy-Weinberg 
equilibrium. Allelic frequencies of these genes and Hardy-
Weinberg equilibrium data are presented in Table 2.  
Population pharmacokinetic modeling 
 
Intravenous and oral CsA data were successfully modeled 
simultaneously. A one-compartment model with 2 transit 
compartments for delayed oral absorption and central elimination 
provided the best fit to the data (Figure 1). The estimated 
parameters were population mean value of clearance (CL), volume 
of distribution (V), log-transformed bioavailability (FLGT) and rate 
constant for transit compartment (ktr). For inter-individual 
variability (IIV), the exponential model for CL and V yielded the 
smallest OBFV and the best visual fitting.  
Demographic, clinical, and genetic polymorphisms data were tested 
during stepwise covariate model building process. However only 
actual body weight was incorporated into CL as power function 
model with the exponent value of 0.419.  
CL = THETA (1) × (weight/70)0.419 × EXP(ETA (1)) 
Although the effects of other demographic, clinical and genetic 
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variables on the pharmacokinetic parameters (CL, V, FLGT, ktr) of 
CsA were evaluated during a stepwise process, significant 
associations were not found. Fluconazole also did not show 
significant effects either individually or compositely with 
voriconazole. 
The final estimate of typical CL, V and ktr was 21.2 L/h, 430 L, and 
2.87 h-1, respectively. The typical value of logit-transformed 
bioavailability of oral CsA was estimated as 1.49 thus the value of 
F1 was 0.81. The final estimated pharmacokinetic parameters, IIV, 




The diagnostic plots of the final model which show the relationship 
between the observed concentrations (DV) and population model-
predicted concentration (PRED) or individual model-predicted 
concentration (IPRED) indicated a good fit between the model and 
the data (Figure 2). The plots of conditional weighted residuals 
(CWRES) vs. PRED and the CWRES vs. time were symmetrically 
distributed and were mostly within 3 units of the null ordinate, 
indicating a good fit of the model to the data (Figure 2). 
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Most of the 1,000 bootstraps ran successfully (82.1%). The 2.5th 
percentile and 97.5th percentile results are described in Table 2. 
The estimates of each value calculated by NONMEM were near the 
center of the bootstrap runs. The pcVPC showed the median and 
95th percentile of the simulated data captures the median and 95th 
percentile of the observed PK data while the simulated 5th 




This study was implemented prospectively to establish a PopPK 
model of CsA in allo-HSCT patients. Although genetic 
polymorphisms may influence CsA pharmacokinetics, only one 
study by Xue et al. has evaluated genetic polymorphisms as 
covariates in allo-HSCT patients.39 Our model is a simpler model 
with fewer proportional residual errors than the previous study. 
Furthermore, we could estimate an absorption rate as ktr because 
most of our data were collected by dense sampling while the 
previous study used a fixed absorption rate. Analysis of CsA 
concentration measured by LC-MS/MS in our study is another 
strength because the immunoassay used in the previous study could 
overestimate CsA concentrations due to cross-reactivity.  
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A one-compartment model with 2 transit absorption compartments 
fitted better than a multi-compartment model because of 
insufficient blood sampling during the terminal elimination phase. A 
transit compartment model might be preferable over a lagged 
absorption model because numerical instability could arise from the 
discontinuous feature of the lagged absorption model.40 Irtan et al. 
and Saint-Marcoux et al. developed transit compartment models for 
CsA in heart, lung, and kidney transplant patients. The mean transit 
time (= ktr / (number of transit compartment + 1)) in our study 
was 0.96 h-1, which is similar to those of previous studies (1.17 h-1 
and 0.88 h-1, respectively).41,42 The CL value in our study ranged 
from 17.8 L/h to 22.7 L/h when weight increased from 46.3 kg to 
82.75 kg and the value is similar to the previously determined CL 
for CsA in allo-HSCT patients (CL = 21.9, 28.2, and 22.3 L/h) and 
cardiopulmonary, liver, and kidney transplant patients (CL = 22.1, 
23.1, and 23.7 L/h, respectively).37,43-47 
The bioavailability of the microemulsion formulation of CsA (Neoral) 
was variable and usually estimated to be about 40%.48 Thus a ratio 
of 2 to 1 was commonly used when patients were switch from 
intravenous to oral CsA.21 However, the estimated bioavailability 
value in our study was relatively high as 81% and similarly high 
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bioavailability values were also reported in previous CsA PopPK 
studies in allo-HSCT patients (71% in two studies and 75.4% in 
another study).39,44,49 When we assumed that oral mucositis after 
the conditioning regimen represents gastrointestinal (GI) 
inflammation, all patients in our study had GI inflammation (only 
four with diarrhea) at the time of blood collection. These patients 
might have high bioavailability because of GI inflammation as 
suggested in previous research.50 CsA maximum concentration was 
65% (P=0.19) and area under the curve of a concentration-time 
graph was 71% (P=0.02) higher in those who had GI 
inflammation.50 There are four factors that might increase CsA 
absorption during inflammatory state. The first one is capillary 
permeability, which is generally increased by inflammation.23 
Second, inflammation may reduce the P-gp mediated multidrug 
resistance efflux function in the intestinal wall epithelium, resulting 
in reduced pumping of CsA from the enterocyte into the intestinal 
lumen.23 Third, CYP3A function and intra cellular metabolism of CsA 
may be decreased within the enterocyte because of inflammation, 
allowing for increased drug absorption.50 Finally, decreased gut 
motility due to inflammation may result in prolonged CsA transit 
through the intestine, leading to increased absorption.50 Although 
49 
 
diarrhea could decrease CsA absorption because of shortened gut 
transit time, the small portion of diarrhea patients did not show 
significant effects on CsA pharmacokinetics in our study. Thus re-
evaluating the conversion ratio of oral CsA might be necessary in 
allo-HSCT protocols. 
The relationship between weight and CsA pharmacokinetics is still 
controversial.37,43,44,49 Jacobson et al. found that weight had a 
significant effect in the CL of CsA in allo-HSCT patients.9 Other 
studies performed in solid organ transplantation patients also found 
an association between weight and the CL of CsA.51-53 However 
Zhou et al. did not find that weight had a significant effect on the CL 
of CsA.54 This may be because the weight of most patients’ in the 
study was mostly in the range of 50–60 kg.54 With a weight range of 
46.3–82.75 kg, we found a significant relationship between weight 
and CL of CsA. The exponent value of 0.419 which reflects the 
effect of weight on CL of CsA was similar to a previous exponent 
value found in Chinese kidney transplant patients.51  
None of the genotype covariates were found to be significant. There 
have been conflicting findings about CYP3A5 and ABCB1 genetic 
effects on CsA pharmacokinetics although several studies have 
been conducted.51,52,54-56 Other candidate covariates also were not 
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considered to be significant in our study, in accordance with 
previous prospective PopPK studies in allo-HSCT. Wilhelm et al. 
and Eljebari et al. evaluated candidate covariates such as weight, 
body surface area, enzyme inducers and inhibitors, age, sex, serum 
creatinine, bilirubin, liver enzymes, and post-transplantation day, 
but did not find any significant covariate in the PopPK model of 
CsA.43,49  
The current study has some limitations. First, blood sampling time 
during oral CsA administration would miss a major part of CsA 
distribution and elimination phases and also potentially the 
enterohepatic recycling profile. Second, patients of the same 
ethnicity and from a single center might cause selection bias in our 
study. Further external validation is needed to apply our model to 
other settings. Third, more caution is needed for interpreting the 
diagnostics because eta-shrinkage was more than 20-30%; that 
means inter-individual variability data were less informative. 
Finally, a small number of patients might reduce the chance of 
finding the genotype-related covariates, which is reflected in 
remaining random error of the final model. However the prospective 
study design had reduced bias and accuracy of the data was the 
strength of this study. Because of the PopPK study design and one 
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compartment model, 34 patients were enough to perform a 
reasonable PopPK of CsA. Bréant et al. noted that for a one 
compartment model with V and CL parameters, 15 to 20 patients 
with 2 blood levels may be enough to perform a reasonable PopPK 
analysis.57  
Our study showed that weight significantly influenced the CL of CsA 
in the model. Thus weight-based dosage regimen of intravenous 
and oral CsA would be appropriate in allo-HSCT patients. However, 
high bioavailability suggests that the conventional oral conversion 
ratio may result in high CsA concentration. Genetic polymorphisms 
did not affect CsA pharmacokinetics in allo-HSCT patients. Further 






Table II-3. Patient demographics (N = 34) 
Male, n (%) 19 (55.9) 
Age, median (range), year 36 (18–62)  
Body weight, mean ± SD, kg 61.0 ± 10.6 
Height, mean± SD, cm 165.4 ± 9.7  
Donor type, n (%) 
Sibling donor 16 (47.1) 
Unrelated donor 17 (50.0) 
Haploidentical donor 1 (2.9) 
Disease type, n (%) 
AML 8 (23.6) 
ALL 10 (29.4) 
ABL 2 (5.9) 
MDS 3 (8.8) 
AA 6 (17.6) 
Others (IMF, NK-cell leukemia, PNH, 
lymphoma) 
5 (14.7) 
Conditioning regimen, n (%) 
Busulfan, cyclophosphamide 13 (38.2) 
Busulfan, fludarabine 16 (47.1) 
Fludarabine, cyclophosphamide 5 (14.7) 
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Laboratory test values, mean ± SD  
Red blood cells, ×106/µL 2.9 ± 0.4  
Hemoglobin, g/dL 9.2 ± 1.3  
Hematocrit, % 27.2 ± 3.9 
Platelets, ×103/µL 100.5 ± 76.8  
Total bilirubin, mg/dL 0.8 ± 0.3 
Alkaline phosphatase, IU/L 81.9 ± 50.8  
Alanine transaminase, IU/L 77.8 ± 84.2  
Aspartate transaminase, IU/L 47.2 ± 54.2  
Serum creatinine, mg/dL 0.95 ± 0.6  
Glomerular filtration rate, mL/min/1.73 m2 98.7 ± 40.6 
Albumin, g/dL 3.6 ± 0.4 
Cholesterol, mg/dL 160.4 ± 39.5  
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; 
ABL, acute biphenotypic leukemia; MDS, myelodysplastic syndrome; 
AA, aplastic anemia; IMF, idiopathic myelofibrosis; PNH, 




Table II-4. Patient’s genotype frequencies 
Gene Variants N (%) P-value 
CYP3A5  *1/*1 23 (67.7) 0.10 
*1/*3 8 (23.5) 
*3/*3 3 (8.8) 
CYP2C19 *1/*1 18 (52.9) 0.26 (*2) 
0.12 (*3) *1/*2 11 (32.4) 
*1/*3 4 (11.8) 
*3/*3 1 (2.9) 
ABCB1 1236C>T CC 2 (5.8) 0.44 
CT 16 (47.1) 
TT 16 (47.1) 
ABCB1 3435C>T CC 13 (38.2) 0.98 
CT 16 (47.1) 
TT 5 (14.7) 
ABCB1 2677G>T/A GG 4 (11.8) 0.09 
GT 15 (44.1) 
GA 8 (23.5) 
TT 5 (14.7) 
AA 1 (2.95) 
AT 1 (2.95) 
ABCC2 
-24C>T 
CC 17 (50.0) 0.54 
CT 13 (38.2) 
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TT 4 (11.8) 
ABCC2 
1249G>A 
GG 30 (88.2) 0.72 
GA 4 (11.8) 
VDR Apal G>T GG 18 (53.0) 0.77 
GT 13 (38.2) 
TT 3 (8.8) 
VDR Bsml G>A GG 29 (85.3) 0.64 
GA 5 (14.7) 













CL (L/h) 21.2 (18) 13.6-28.8 21.6 (9.7-29.8) 
V (L) 430 (33) 146-714 446 (224-803) 
FLGT 1.49 (80) -0.89-3.87 1.93 (0.36-11.8) 
ktr (h
-1) 2.87 (31) 1.09-4.65 2.92 (1.43-4.36) 
Impact of 
weight on CL  
0.419 (42) 0.067-0.771 0.449 (0.02-1.44) 
IIV of CL 
(CV%) 
40.2 (33) 13.7-66.7 39.5 (4.6, 67.1) 




13.2 (41) 2.4-24.0 15.0 (1.2-40.0) 
Additive 
(ng/mL) 
35.8 (77) -19-91 42.6 (1.5-149.2) 
CI, confidence interval; CL, clearance; CV, coefficient of variation; 
FLGT, log-transformed bioavailability; IIV, inter-individual 
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variability; ktr, rate constant for transit compartment; RSE, relative 
























1. 가톨릭조 모 포 행, 한국조 모 포 행 회 통계, 2015 
2. Felfly H, Haddad GG. Hematopoietic stem cells: potential 
new applications for translational medicine. J Stem Cells. 
2014;9(3):163-97 
3. Park B, Yoo KH, Kim C. Hematopoietic stem cell expansion 
and generation: the ways to make a breakthrough. Blood 
Res. 2015;50(4):194-203. 
4. Goker H, Haznedaroqlu IC, Chao NJ. Acute graft-vs-host 
disease: pathobiology and management. Exp Hematol. 
2001;29(3):259-77. 
5. Harris AC, Ferrara JL, Levine JE. Advances in predicting 
acute GVHD. Br J Haematol. 2013;160(3):288-302. 
6. Sung AD, Chao NJ. Concise review: acute graft-versus-
host disease: immunobiology, prevention, and treatment. 
Stem Cells Transl Med. 2013;2(1):25-32. 
7. Choi SW, Reddy P. Current and emerging strategies for the 
prevention of graft-versus-host disease. Nat Rev Clin 
Oncol. 2014;11(9):536-47. 
8. Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and 
62 
 
treatment of GVHD: EBMT-ELN working group 
recommendations for a standardized practice. Bone 
Marrow Transplant. 2014;49(2):168-73. 
9. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord 
blood transplantation after nonmyeloablative conditioning: 
impact on transplantation outcomes in 110 adults with 
hematologic disease. Blood. 2007;110(8):3064-70. 
10. Ram R, Galter-Gvili A, Yeshurun M, et al. Prophylaxis 
regimens for GVHD: systematic review and meta-analysis. 
Bone Marrow Transplant. 2009;43(8):643-53. 
11. Jacobsohn DA. Acute graft-versus-host disease in 
children. Bone Marrow Transplant. 2008;41(2):215-21. 
12. Peters C, Minkov M, Gadner H, et al. Statement of current 
majority practices in graft-versus-host disease 
prophylaxis and treatment in children. Bone Marrow 
Transplant. 2000;26(4):405-11. 
13. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus 
Conference on Acute GVHD Grading. Bone Marrow 
Transplant. 1995;15(6):825-8. 
14. Naranjo CA, Busto U, Sellers EM, et al. A method for 
estimating the probability of adverse drug reactions. Clin 
63 
 
Pharmacol Ther. 1981;30(2):239-45. 
15. Sakai R, Taguri M, Oshima K, et al. A comparison of 
tacrolimus and cyclosporine combined with methotrexate 
for graft-versus-host disease prophylaxis, stratified by 
stem cell source: a retrospective nationwide survey. Int J 
Hematol. 2016;103(3):322-33. 
16. Inamoto Y, Flowers ME, Wang T, et al. Tacrolimus versus 
Cyclosporine after Hematopoietic Cell Transplantation for 
Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 
2015;21(10):1776-82. 
17. Sabapathy C, Gourde JA, Khan SP, et al. Tacrolimus with 
mini-methotrexate as prophylaxis for graft-versus-host 
disease in pediatric patients after allogeneic peripheral 
blood stem cell transplant or bone marrow transplant. J 
Pediatr Hematol Oncol. 2008;30(12):945-9. 
18. Yanik G, Levine JE, Ratanatharathorn V, et al. Tacrolimus 
(FK506) and methotrexate as prophylaxis for acute graft-
versus-host disease in pediatric allogeneic stem cell 
transplantation. Bone Marrow Transplant. 
2000;26(2):161-7. 
19. Curcioli AC, de Carvalho EC. Infusion of hematopoietic 
64 
 
stem cells: types, characteristics, adverse and transfusion 
reactions and the implications for nursing. Rev Lat Am 
Enfermagem. 2010;18(4):716-24. 
20. Staatz CE, Tett SE. Clinical pharmacokinetics and 
pharmacodynamics of tacrolimus in solid organ 
transplantation. Clin Pharmacokinet. 2004;43(10):623-53. 
21. Atkinson K, Biggs JC, Britton K, et al. Oral administration 
of cyclosporin A for recipients of allogeneic marrow 
transplants: implications of clinical gut dysfunction. Br J 
Haematol. 1984;56:223-31. 
22. Lu H, Rosenbaum S. Developmental pharmacokinetics in 
pediatric populations. J Pediatr Pharmacol Ther. 
2014;19(4):262-76. 
23. Jacobson P, Ng J, Ratanatharathorn V, et al. Factors 
affecting the pharmacokinetics of tacrolimus (FK506) in 
hematopoietic cell transplant (HCT) patients. Bone Marrow 
Transplant. 2001;28(8):753-8. 
24. Xue L, Rui JZ, Zhang Y, et al. Population pharmacokinetic 
study of tacrolimus in patients with hematopoietic stem 
cell transplant. Yao Xue Xue Bao. 2009;44(10):1145-51. 
25. Wallin JE, Friberg LE, Fasth A, et al. Population 
65 
 
pharmacokinetics of tacrolimus in pediatric hematopoietic 
stem cell transplant recipients: new initial dosage 
suggestions and a model-based dosage adjustment tool. 
Ther Drug Monit. 2009;31(4):457-66. 
26. Liu XD, Chen J. Prediction of drug clearance in humans 
from laboratory animals based on body surface area. Eur J 
Drug Metab Pharmacokinet. 2001;26(4):249-55. 
27. Hempel G, Boos J. Flat-fixed dosing versus body surface 
area based dosing of anticancer drugs: there is a 
difference. Oncologist. 2007;12(8):924-6. 
28. Isoherranen N, Kunze KL, Allen KE, et al. Role of 
itraconazole metabolites in CYP3A4 inhibition. Drug Metab 
Dispos. 2004;32(10):1121-31. 
29. Duncan N, Craddock C. Optimizing the use of cyclosporin in 
allogeneic stem cell transplantation. Bone Marrow 
Transplant. 2006;38:169-74. 
30. Andrews DJ, Cramb R. Cyclosporin: revisions in monitoring 
guidelines and review of current analytical methods. Ann 
Clin Biochem. 2002;39:424-35. 
31. Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH. The 
effect of CYP3A5 polymorphism on dose-adjusted 
66 
 
cyclosporine concentration in renal transplant recipients: a 
meta-analysis. Pharmacogenomics J. 2011;11:237-46. 
32. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. 
Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated 
by the vitamin D receptor pathway in primary human 
hepatocytes. J Biol Chem. 2002;277:25125-32. 
33. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, 
Pastan I, Gottesman MM. Biochemical, cellular, and 
pharmacological aspects of the multidrug transporter. Annu 
Rev Pharmacol Toxicol. 1999;39:361-98. 
34. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of 
MDR1 and its impact on the pharmacokinetics and 
pharmacodynamics of drugs. Pharmacogenomics. 
2003;4:397-410. 
35. Niwa T, Yamamoto S, Saito M, Shiraga T, Takagi A. Effect 
of cyclosporine and tacrolimus on cytochrome p450 
activities in human liver microsomes. Yakugaku 
Zasshi. 2007;127:209-16. 
36. Barbarino JM, Staatz CE, Venkataramanan R, Klein 
TE, Altman RB. 
PharmGKB summary: cyclosporine and tacrolimus pathways. 
67 
 
Pharmacogenet Genomics. 2013;23:563-85. 
37. Jacobson PA, Ng J, Green KG, Rogosheske J, Brundage R. 
Posttransplant day significantly influences 
pharmacokinetics of cyclosporine after hematopoietic stem 
cell transplantation. Biol Blood Marrow Transplant. 
2003;9:304-11. 
38. Duncan N, Arrazi J, Nagra S, Cook M, Thomson 
AH, Craddock C. Prediction of intravenous cyclosporine 
area under the concentration-time curve after allogeneic 
stem cell transplantation. Ther Drug Monit. 2010;32:353-
8.  
39. Xue L, Zhang WW, Ding XL, Zhang JJ, Bao JA, Miao LY. 
Population pharmacokinetics and individualized dosage 
prediction of cyclosporine in allogeneic hematopoietic stem 
cell transplant patients. Am J Med Sci. 2014;348:448-54. 
40. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 
Implementation of a transit compartment model for 
describing drug absorption in pharmacokinetic studies. J 
Pharmacokinet Pharmacodyn. 2007;34:711-26. 
41. Irtan S, Saint-Marcoux F, Rousseau A, et al. Population 
pharmacokinetics and bayesian estimator of cyclosporine 
68 
 
in pediatric renal transplant patients. Ther Drug Monit. 
2007;29:96-102. 
42. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. 
Patient characteristics influencing ciclosporin 
pharmacokinetics and accurate Bayesian estimation of 
ciclosporin exposure in heart, lung and kidney transplant 
patients. Clin Pharmacokinet. 2006;45:905-22. 
43. Eljebari H, Gaies E, Fradj NB, et al. Population 
pharmacokinetics and Bayesian estimation of cyclosporine 
in a Tunisian population of hematopoietic stem cell 
transplant recipient. Eur J Clin Pharmacol. 2012;68:1517-
24. 
44. Zhou H, Gao Y, Cheng XL, Li ZD. Population 
pharmacokinetics of cyclosporine A based on NONMEM in 
Chinese allogeneic hematopoietic stem cell transplantation 
recipients. Eur J Drug Metab Pharmacokinet. 
2012;37:271-8. 
45. Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F. Population 
pharmacokinetics of cyclosporine in cardiopulmonary 
transplant recipients. Ther Drug Monit. 2005;27:116-22. 
46. Sun B, Li XY, Gao JW, et al. Population Pharmacokinetic 
69 
 
Study of Cyclosporine Based on NONMEM in Chinese 
Liver Transplant Recipients. Ther Drug Monit. 
2010;32:715-22. 
47. Tokui K, Kimata T, Uchida K, et al. Dose adjustment 
strategy for oral microemulsion formulation of 
cyclosporine - Population pharmacokinetics-based 
analysis in kidney transplant patients. Ther Drug Monit. 
2004;26:287-94. 
48. Parquet N, Reigneau O, Humbert H, et al. New oral 
formulation of cyclosporin A (Neoral) pharmacokinetics in 
allogeneic bone marrow transplant recipients. Bone 
Marrow Transplant. 2000;25:965-8. 
49. Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen JJ, Huijgens 
PC, Swart EL. Population pharmacokinetics of ciclosporin 
in haematopoietic allogeneic stem cell transplantation with 
emphasis on limited sampling strategy. Br J Clin Pharmacol. 
2012;73:553-63. 
50. Schultz KR, Nevill TJ, Balshaw RF, et al. Effect of 
gastrointestinal inflammation and age on the 
pharmacokinetics of oral microemulsion cyclosporin A in 
the first month after bone marrow transplantation. Bone 
70 
 
Marrow Transplant. 2000;26:545-51. 
51. Chen B, Zhang W, Gu Z, Li J, Zhang Y, Cai W. Population 
pharmacokinetic study of cyclosporine in Chinese renal 
transplant recipients. Eur J Clin Pharmacol. 2011;67:601-
12. 
52. Hesselink DA, van Gelder T, van Schaik RH, et al. 
Population pharmacokinetics of cyclosporine in kidney and 
heart transplant recipients and the influence of ethnicity 
and genetic polymorphisms in the MDR-1, CYP3A4, and 
CYP3A5 genes. Clin Pharmacol Ther. 2004;76:545-56. 
53. Yin OQ, Lau SK, Chow MS. Population pharmacokinetics of 
cyclosporine in chinese cardiac transplant recipients. 
Pharmacotherapy. 2006;26:790-7. 
54. Song J, Kim MG, Choi B, et al. CYP3A5 polymorphism 
effect on cyclosporine pharmacokinetics in living donor 
renal transplant recipients: analysis by population 
pharmacokinetics. Ann Pharmacother. 2012;46:1141-51. 
55. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 
and MDR1 polymorphic expression on cyclosporine oral 




56. Fruit D, Rousseau A, Amrein C, et al. Ciclosporin 
population pharmacokinetics and Bayesian estimation in 
thoracic transplant recipients. Clin Pharmacokinet. 
2013;52:277-88. 
57. Breant V, Charpiat B, Sab JM, Maire P, Jelliffe RW. How 
many patients and blood levels are necessary for 
population pharmacokinetic analysis? A study of a one 








이식편 주질  에  




약학과 임상약학 공 
울 학  학원 
 
1. 소아 조 모 포이식 자에  타크 리 스(tacrolimus)  
사이클 스포린(cyclosporin)  효과, 안   임상 연구 
 
액종양질 에  조 모 포이식  질병 를 한 일한 
법  림프구 병  포함한 소아 액종양질  자에  
번히 사용 고 있다. 그러나 조 모 포이식  인해 생하는 
이식편 주질 (graft versus host disease), 그 에 도 특히 이식 
후 100일 이내에 생하는 II~IV 등   이식편 주질   
생존 간과 이식  사망 에 한 연 이 있는 합병증이다. 
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칼시뉴린억 (calcineurin inhibitor)에 속하는 
타크 리 스(tacrolimus)  사이클 스포린(cyclosporin)  
조 모 포이식 후 이식편 주질   목  일  
사용 는 면역조 이다. 재 소아 조 모 포이식 자에 해 는 
‘EBMT(European Group for Blood and Marrow 
Transplantation)‘에  사이클 스포린/ 토트 이트(methotrexate) 
요법  이식편 주질   일차  요법  추천하고 있다. 
그러나 타크 리 스  면역조 요법에 한 연구가 증가함에 
라, 근에 행  타 분  연구에 는 타크 리 스 병용요법이 
사이클 스포린 병용요법보다 이식편 주질  에 효과 임이 
보고하고 있다. 타 분 에 포함  존에 행   약 간   
임상 연구는 주  인  상  행 었 며, 소아 조 모 포이식 
자에 도 타크 리 스가 사이클 스포린에 해 이식편 주질  
에  효과 이고 안 할 것인지에 해 는 립 어 있지 않다. 
라  본 연구는 소아 조 모 포이식 자에  타크 리 스  
사이클 스포린  안 과 효  하  하여 행 었다. 
본 연구는 향  다  조군  연구  2011 부  
2013 지 3개 병원에  행 었다. 연구 참여 상자는 연간 
동종 조 모 포 이식 후 생하는 이식편 주질   필요  
하는 악 액질  자  이식 시 연 이 만 18  이하인 남아 또는 
여아, 액학  질  연간 동종 조 모 포 이식   자  
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하 다. 피험자 는 35%  이식편 주질  생  차이를 
검 하  해 탈락  고 하여 각 군당 26명씩 산출하 다.  
본 연구  1차 효  평가변 는 피부, 간, 장  II~IV 등  
 이식편 주질  생  Keystone criteria에 라 
평가하 고, 안  평가변 는 이상  생 도  감염  생 
도를 평가하 다. 통계 분  해 SPSS version 19를 사용하 며, 
modified intention-to-treat (ITT) 분  통해 P < 0.05 일  
통계  한 것  하 다. 
본 연구에 모집  자  이식 후 생착이 일어나지 않아 
이식편 주질 이 생하지 않는 자를 외한 modified ITT 
집단(타크 리 스군 18명, 사이클 스포린군 21명)에 하여 분  
시행하 다. 상 임상시험 상자  인구학  특 (나이, 별, 키, 
체 , 진단명, 조 모 포 원, HLA 합도)는  집단에  통계  
한 차이가 없었다. 
1차 효  평가변 인 Ⅱ~Ⅳ 등   이식편 주질  χ2과 
Fisher’s exact test에 라 타크 리 스군  83.3%(n=13), 
사이클 스포린군  66.7%(n=14)에  생하 나 한 차이를 
보이지는 않았다 (p=0.29). 도탈락  자를 고 한 Ⅱ~Ⅳ 등  
이식편 주질  생  Kaplan-Meier test  분 하   
타크 리 스군  83.3%, 사이클 스포린군  74.8%에  Ⅱ~Ⅳ 
등  이식편 주질 이 생하 며, 역시 한 차이는 보이지 
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않았다 (p=0.994). III~Ⅳ 등  증  이식편 주질  χ2과 
Fisher’s exact test에 라 타크 리 스군  27.8%(n=5), 
사이클 스포린군  19.0%(n=4)에  생하 나 한 차이를 
보이지는 않았다 (p=0.71).  
타크 리 스나 사이클 스포린  인해 생하는 이상  
Naranjo scale  평가하여 “probable” 또는 “definite”인 것만 
포함하 다. 타크 리 스군에 는 “probable” 크 아티닌 상승이 
2명, 심이 1명에  생하 고, 사이클 스포린군에 는 “probable” 
피부 진이 1명에  생하 다. 타크 리 스군  1명에 는 
이식편 주질  료 목  시 리 스(sirolimus)가 병용 었고, 
이  인하여 미 병증(thrombotic microangiopathy)이 
생하여 약 이 단 었다. 
감염 는 거 포 이러스(cytomegalovirus)에 한 
항원 증(antigenemia) 또는 감염이 타크 리 스군 61.1%(n=11), 
사이클 스포린군  19.0%(n=4)  가장 많  도  보고 었다.  
결  임상시험 결과, 타크 리 스는 존 사이클 스포린  
요법에 하여 우월  입증하지 못하 나 슷한 효과를 보 므 , 
소아 자에  타크 리 스  사용  인 할  있다.  
 




타크 리 스  농도는 이식편 주질  에 요한 인자이다. 
그러나 타크 리 스는 개체간  개체내 약 농도  차이가 큰 약 , 
TDM  통하여 목  한 조 하 하 나 실  목  농도를 
지하지 못하는 자  경구   후 약 농도가 높아 일시 단하는 
자가 많았다. 타크 리 스  효  보장하  하여, 약  
농도는 목 료 지하는 것이 요하다.  
조 모 포이식 자는 처  여  항암 , 이식편 주질 , 
감염 등  생하는 장  막염  장벽  손상, 그리고 CYP 
억 인 항진균  병용  약    사가 고 장 이식 
자 는 다르다. 게다가 소아는 인과 장  능  사 효소  달 
차이  약동학  차이가 생할  있다. 그럼에도 불구하고 존  
연구에  소아 자를 상  진행  집단 약동학 연구는 1건 에 
없었 며 22명  소  자만  포함하 다. 게다가 해당 연구에 는 
약  상 작용  고 하지 않았다. 라  본 연구에 는 소아 
조 모 포이식 자에  타크 리 스  집단 약동학 모델  
구축하고자 한다. 
본 연구는 후향  2006  9월부  2015  2월 지 
울 학 병원에  조 모 포이식  고 이식편 주질   
목  타크 리 스를 여  18  미만  소아 자를 
포함하 다.  
타크 리 스는 0.03 mg/kg/day 용량  이식 하루 부  8 
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mL/h 속도  지속 주입하며, 이식 21일 후부  경구  하 다. 
경구 용량  마지막 지속 주입 용량  약 4  1일 2회 분할하여 
여하 다. 타크 리 스  용량  TDM  통하여 농도인 10-20 
ng/ml에 도달하도  용량  조 하 다. 집단 약동학 모델  종속 
변 인 타크 리 스  농도는 울 학 병원에  liquid 
chromatography-tandem mass spectrometry (LC-MS/MS)  
한 TDM 분  결과를 사용하 다. 
공변량 평가를 하여 자  나이, 별, 체 , 키, 체 면 , 이식 후 
간, 구, 헤모 , 구용 , 소 , 요소질소, 
크 아티닌,  리루 , 알칼리인산분해효소, 알라닌 아미노 이효소, 
아스 라진산 아미노 이효소, 장  이식편 주질 여부, 그리고 
병용 는 azole계 항진균 , 프 톤펌프억 , 칼슘채 차단 , 
페니토인(phenytoin), 스 이드 보를 집하 다. 
집단 약동학 모델  NONMEM version 7.3  통해 구축하 며, 1-
컴 트 트 모델과 2-컴 트 트 모델  하고, 다양한  
모델(단  , 지연 시간 용 모델, 트랜싯 컴 트 트 모델)  
하 다.  100일간  추 찰 간에 하여 이식 후 1개월간  
매주, 이후 매달  간  나 어 inter-occasional variability (IOV)를 
용하 다. 개체 간 차이는 exponential 모델  용하 다. 
집한 보는 향  택과 후향  거 법  평가하여 
타크 리 스  약동학에 통계  한 향  주는 공변량  
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택하 며,  향  택에  p <0.05, 즉 objective function 
value (OFV) 3.84, 후향  거에  p <0.01, 즉 OFV 6.63  
 하 다. 종  택  모델  내  타당  bootstrap과 
visual predictive check를 통해 평가하 다. 
본 모델  1-컴 트 트 모델이 사용 었다. 부분  채 이 경구 
복용  채 직 에 시행 었  에 trough 농도 며,  모델  
단  모델  속도상 가 헌 값인 4.48 h-1  고 었다.  
향  택  과 에  azole계 항진균  사용여부를 clearance 
(CL)에 공변량  포함하   OFV를 가장 크게 감소시 며 (-
134.5), 이후 체 면 이 CL  volume of distribution (V)에 
공변량  포함 었다. 후향  거에  거  공변량  없었다. 
라  종 모델  다 과 같이 구축 었다.  
CL = 6.74 × (체 면 /1.102)0.552 × 0.4(azole계 항진균 를 
사용하는 경우) 
V = 1160 × (체 면 /1.102)0.503 
종 모델  bootstrap 결과는 실  값  잘 추 함  보 며, 
visual predictive check 결과도 40일 이후  5 percentile 값이 낮게 
추 는 경향이 있 는 하 지만, median 값이나 95 percentile 값 
등  잘 추 어 좋  모델  평가 었다.  
결  본 연구를 통하여 소아 조 모 포이식 자에  한 
약 농도 조  한 타크 리 스  집단 약동학 모델이 개 었다. 
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추  생체이용 이 37%  존에 일  사용 는 25%보다 높아 
경구  시 높  약  농도  원인이  것  생각 다. 또한 
azole계 항진균  사용이 CL를 40% 지 감소시  약 용량 에 
어야 하며, 자  체 면  고 해야 한다. 
 
3. 인 조 모 포이식 자에  사이클 스포린 집단 약동학 연구 
 
이식편 주질   해 사용 는 사이클 스포린  좁  
료역  가지며, 약동학  개체 간, 개체 내 차이가 큰 약 이다. 
특히 많  연구들에  보고하 듯이 사이클 스포린  약동학에는 
약 사에 여하는 CYP3A5*3 변이나 약  송체인 P-
glycoprotein  에 여하는 ABCB1 자  다 이 여할  
있다.  
이러한 개체 간 차이  인해 사이클 스포린 농도를 부작용  
소 하며 이식편 주질  할  있는 면역억 작용  
나타내도  조 하 란 어 다. 집단 약동학 연구는 개체 간 차이를 
하고 모델  구축함 써 개인 맞춤 용량  하는데 뛰어난 
법이다. 근 지도 사이클 스포린에 한 집단 약동학 연구는 
고 장 이식 자를 상  많이 행 었다. 그러나 조 모 포이식 
자는 처  여  항암 , 이식편 주질 , 감염 등  약  
 CYP 억 인 항진균  병용  약  사가 
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고 장 이식 자 는 다르다. 라  본 연구에 는 조 모 포이식 
자에   다  고 한 사이클 스포린  집단 약동학 모델  
구축하고자 하 다. 
본 연구는 2009  11월부  2011  3월 지 울 학 병원에  
조 모 포이식  고 사이클 스포린  여  18  이상  인 
자를 상  하 다. 사이클 스포린  이식 1~2일 부  3 mg/kg 
용량  24시간 지속 주입하 고, 이식 21일 후부  일 여량  
2~3 를 1일 2회 분할 여한 후 복용하 다. 사이클 스포린  용량  
TDM  통해 150~400 ng/mL  조 었다. 사이클 스포린 농도 
분  한 액 검체 1 mL를 지속 주입  한 시 과 경구 복용 간 
 복용 직 , 복용 1, 2, 3, 4, 5 시간 후에 집하 다. 
사이클 스포린  농도는 LC-MS/MS  하 다. 
집단 약동학 모델 구축  하여 자  나이, 별, 체 , 키, 구, 
헤모 , 구용 , 소 ,  리루 , 알칼리인산분해효소, 
알라닌 아미노 이효소, 아스 라진산 아미노 이효소, 청 크 아티닌, 
사구체여과 , 알부민, 스  , 병용하는 스 이드 용량과 
CYP 상 작용 약 들  집하 다. 자는 조 모 포이식 에 
집한 액 검체를 사용하 며, TaqMan 또는 SNaPshot assay를 
통해 분 었다.  
집단 약동학 모델 구축   합효과 모델링 프 그램인 
NONMEM version 7.2를 통해 행 었다. 1 또는 2-컴 트 트 
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모델과 다양한 모델이 본 모델  평가 었 며, 생체이용  
0~1 사이  값  가지도  짓 변 (logit transformation) 하 다. 
개체 간 약동학 라미  차이는 additive, proportional, exponential 
모델  었다. 집한 보를 향 과 후향  법  평가하여 
사이클 스포린  약동학에 한 공변량  평가하 다. 향 과 
후향  택   p <0.05인 OFV  변 량 3.84  하 다.  
구축  종 모델  평가는 bootstrap과 visual predictive check 
법  통해 행하 며 PsN (Perl speaks NONMEM version. 
4.2.0)과 R software 프 그램  사용하 다. 
본 연구에 포함  자는  34명  분   모  Hardy-
Weinberg equilibrium  만족하 다. CYP 상 작용 약 는 
플루 나졸(fluconazole)이 19명  자에  지속 주입 간 동안 
사용 었고, 보리 나졸(voriconazole)이 2명  자에  경구복용 
간 동안 사용 었다.  
본 모델  2개  트랜싯 컴 트 트(transit compartment)를 통해 
지연 를 명하는 1-컴 트 트 모델이 구축 었 며, clearance 
(CL), volume of distribution (V), log-transformed bioavailability 
(FLGT)  rate constant for transit compartment (ktr)  약동학 
라미 가 추 었다. 개체 간 다양  CL  V에 exponential 
모델  포함 었다. 종 모델에는 체 이 CL에 power function 모델  
포함 었 며 지 값  0.419이었다.  
82 
 
CL = 21.2 × (weight/70)0.419 
다른 임상 ,  지 는 사이클 스포린  집단 약동학 모델에 
포함 지 않았다. 종 모델에  도출  CL, V, ktr  추 값  각각 
21.2 L/h, 430 L, 2.87 h-1이며, 생체이용  추 는 81%이었다. 종 
모델  bootstrap 결과  visual predictive check도  2.5 
percentile 값과 97.5 percentile 값이 실  값  포함하여 모델  
내  타당 도 검증 었다. 
결과  본 연구를 통하여 인 조 모 포이식 자에  
사이클 스포린  집단 약동학 모델  구축하 며, CL에 체 이 
공변량  향   인하 다. 평가한  사이클 스포린  
약동학에 향  주지 않았 며 본 연구에  구축한 모델  탕  
조 모 포이식 자에  한 이식편 주질  요법  시행할 
 있  것이다. 
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